Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
05 janv. 2023 16h30 HE
|
Pacira BioSciences
TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference at 3:00 PM PT (6:00PM...
Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022
13 déc. 2022 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
14 nov. 2022 08h00 HE
|
Pacira BioSciences
-- EXPAREL average daily sales for October 2022 were 106 percent of October 2021 -- TAMPA, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in...
Pacira BioSciences to Present at Two Healthcare Conferences in November
08 nov. 2022 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare...
Pacira BioSciences Reports Third Quarter 2022 Financial Results
03 nov. 2022 08h00 HE
|
Pacira BioSciences
-- Third quarter revenue of $167 million, increased 31% over prior year ---- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc....
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
20 oct. 2022 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on...
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
13 oct. 2022 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expanded Access to EXPAREL for Patients Undergoing Oral and Maxillofacial Procedures
27 sept. 2022 08h00 HE
|
Pacira BioSciences
TAMPA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sevāredent Sourcing Solutions, a Group Purchasing Organization (GPO) that creates a competitive advantage for like-minded dental organizations through...
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy
21 sept. 2022 08h00 HE
|
Pacira BioSciences
-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- --...